ERBB2 and breast carcinoma: Recently, there has been a major need to better understand the biological characteristics of triple-negative (estrogen receptor [ER]-negative, progesterone receptor [PR]-negative, and human epidermal growth factor receptor 2 [HER2]-negative) breast cancer, which accounts for 15% to 20% of newly diagnosed breast cancer cases [10–12].